ZA200201621B - Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (HRT). - Google Patents
Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (HRT). Download PDFInfo
- Publication number
- ZA200201621B ZA200201621B ZA200201621A ZA200201621A ZA200201621B ZA 200201621 B ZA200201621 B ZA 200201621B ZA 200201621 A ZA200201621 A ZA 200201621A ZA 200201621 A ZA200201621 A ZA 200201621A ZA 200201621 B ZA200201621 B ZA 200201621B
- Authority
- ZA
- South Africa
- Prior art keywords
- estrogen
- mesoprogestin
- hrt
- mesoprogestins
- substance
- Prior art date
Links
- 238000002657 hormone replacement therapy Methods 0.000 title claims description 31
- 239000000203 mixture Substances 0.000 title claims description 22
- 239000002379 progesterone receptor modulator Substances 0.000 title description 2
- 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 title description 2
- 229940011871 estrogen Drugs 0.000 claims description 76
- 239000000262 estrogen Substances 0.000 claims description 75
- 238000011282 treatment Methods 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 13
- 229960005309 estradiol Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 6
- 229960002568 ethinylestradiol Drugs 0.000 claims description 6
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 5
- -1 J 912 Chemical compound 0.000 claims description 5
- 229930182833 estradiol Natural products 0.000 claims description 5
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 4
- 239000005426 pharmaceutical component Substances 0.000 claims description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 33
- 230000000694 effects Effects 0.000 description 25
- 239000008177 pharmaceutical agent Substances 0.000 description 19
- 239000000583 progesterone congener Substances 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 14
- 239000000186 progesterone Substances 0.000 description 14
- 229960003387 progesterone Drugs 0.000 description 14
- 210000000988 bone and bone Anatomy 0.000 description 13
- 239000003418 antiprogestin Substances 0.000 description 12
- 210000004696 endometrium Anatomy 0.000 description 12
- 230000001076 estrogenic effect Effects 0.000 description 12
- 230000001833 anti-estrogenic effect Effects 0.000 description 11
- 230000000708 anti-progestin effect Effects 0.000 description 11
- 239000000044 progesterone antagonist Substances 0.000 description 11
- 239000000306 component Substances 0.000 description 10
- 239000000328 estrogen antagonist Substances 0.000 description 10
- 230000009245 menopause Effects 0.000 description 10
- 206010001928 Amenorrhoea Diseases 0.000 description 9
- 239000004015 abortifacient agent Substances 0.000 description 9
- 231100000641 abortifacient agent Toxicity 0.000 description 9
- 230000001270 agonistic effect Effects 0.000 description 9
- 230000002357 endometrial effect Effects 0.000 description 9
- 230000035935 pregnancy Effects 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 229940046836 anti-estrogen Drugs 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 102000003998 progesterone receptors Human genes 0.000 description 8
- 108090000468 progesterone receptors Proteins 0.000 description 8
- 229960001603 tamoxifen Drugs 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 230000001838 anti-progestagenic effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000000757 progestagenic effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 241000700198 Cavia Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 206010014733 Endometrial cancer Diseases 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 206010000210 abortion Diseases 0.000 description 3
- 231100000176 abortion Toxicity 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 231100000319 bleeding Toxicity 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000000748 cardiovascular system Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229940035811 conjugated estrogen Drugs 0.000 description 3
- 239000007933 dermal patch Substances 0.000 description 3
- 201000003914 endometrial carcinoma Diseases 0.000 description 3
- 238000009164 estrogen replacement therapy Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 238000011554 guinea pig model Methods 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- WFHDOIKSUKQTLH-IBXXTFBESA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;[(8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentanoate Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 WFHDOIKSUKQTLH-IBXXTFBESA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- KDYQVUUCWUPJGE-UHFFFAOYSA-N Ethamoxytriphetol Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(O)(C=1C=CC=CC=1)CC1=CC=C(OC)C=C1 KDYQVUUCWUPJGE-UHFFFAOYSA-N 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 description 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- RVKFQAJIXCZXQY-CBZIJGRNSA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] sulfamate Chemical compound NS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 RVKFQAJIXCZXQY-CBZIJGRNSA-N 0.000 description 1
- YXYXCSOJKUAPJI-ZBRFXRBCSA-N [(8r,9s,13s,14s,17s)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] sulfamate Chemical compound NS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 YXYXCSOJKUAPJI-ZBRFXRBCSA-N 0.000 description 1
- AUYLVPGDOVEOML-UHFFFAOYSA-N [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(piperidin-1-ylmethoxy)phenyl]methanone Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 AUYLVPGDOVEOML-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000001911 anti-progestational effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000006406 biphasic response Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940108922 climara Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001359 estradiol 3-benzoate Drugs 0.000 description 1
- 150000002159 estradiols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000004748 mammary carcinogenesis Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940110234 mirena Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 229950002366 nafoxidine Drugs 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 229940094984 other estrogen in atc Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011452 sequencing regimen Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940044959 vaginal cream Drugs 0.000 description 1
- 239000000522 vaginal cream Substances 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38614099A | 1999-08-31 | 1999-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200201621B true ZA200201621B (en) | 2004-08-25 |
Family
ID=23524333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200201621A ZA200201621B (en) | 1999-08-31 | 2002-02-26 | Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (HRT). |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1605924B1 (sh) |
| JP (1) | JP2003513908A (sh) |
| KR (1) | KR100729311B1 (sh) |
| CN (1) | CN1454088A (sh) |
| AR (1) | AR025456A1 (sh) |
| AT (1) | ATE413168T1 (sh) |
| AU (1) | AU781836B2 (sh) |
| BG (1) | BG65846B1 (sh) |
| BR (1) | BR0013710A (sh) |
| CA (1) | CA2383659C (sh) |
| CO (1) | CO5200773A1 (sh) |
| CZ (1) | CZ301412B6 (sh) |
| DE (1) | DE60040764D1 (sh) |
| EA (1) | EA007840B1 (sh) |
| EE (1) | EE200200102A (sh) |
| ES (1) | ES2316402T3 (sh) |
| HR (1) | HRP20020266A2 (sh) |
| HU (1) | HUP0202460A3 (sh) |
| IL (2) | IL148417A0 (sh) |
| LT (1) | LT5011B (sh) |
| LV (1) | LV12942B (sh) |
| MX (1) | MXPA02002190A (sh) |
| NO (1) | NO20021000L (sh) |
| NZ (1) | NZ517469A (sh) |
| PE (1) | PE20010581A1 (sh) |
| PL (1) | PL198798B1 (sh) |
| RO (1) | RO122180B1 (sh) |
| RS (1) | RS50396B (sh) |
| SI (1) | SI20851B (sh) |
| SK (1) | SK287121B6 (sh) |
| UA (1) | UA75339C2 (sh) |
| WO (1) | WO2001034126A2 (sh) |
| ZA (1) | ZA200201621B (sh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1525215T3 (da) * | 2002-08-02 | 2007-01-15 | Schering Ag | Modulatorer for receptoren for progesteron med forhöjet anti-gonadotrop aktivitet til fertilitetskontrol hos kvinder og ved terapi til erstatning af hormoner |
| DE10236405A1 (de) | 2002-08-02 | 2004-02-19 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie |
| US20040097591A1 (en) * | 2002-11-18 | 2004-05-20 | Kristof Chwalisz | Use of selective progesterone receptor modulators for the treatment of androgen deficiency |
| RU2611370C1 (ru) * | 2016-01-12 | 2017-02-21 | Общество с ограниченной ответственностью Медицинская Корпорация "РАНА" | Применение препарата Лаеннек для уменьшения или устранения проявления менопаузальных симптомов (варианты) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2054271A (en) | 1932-05-17 | 1936-09-15 | Schering Kahlbaum Ag | Production of crystallized hormone esters |
| DE699310C (de) | 1936-11-20 | 1940-11-27 | Chemische Ind Ges | Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols |
| US2225419A (en) | 1937-03-01 | 1940-12-17 | Schering Corp | Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols |
| US2611773A (en) | 1951-08-21 | 1952-09-23 | Upjohn Co | Estradiol 17-cyclopenetanepropionate |
| US2990414A (en) | 1957-03-26 | 1961-06-27 | Syntex Sa | 17-undecenoate of estradiol |
| US4729999A (en) * | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
| MX9301121A (es) * | 1992-03-02 | 1993-09-01 | Schering Ag | Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina. |
| TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| DE4225623C2 (de) * | 1992-08-03 | 1994-06-30 | Karl Hehl | Verfahren zur Herstellung einer pulverförmigen Spritzgußmasse für die Herstellung von Porzellan und deren Verwendung |
| US5468736A (en) * | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
| DE4332283A1 (de) * | 1993-09-20 | 1995-04-13 | Jenapharm Gmbh | Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DE4332284C2 (de) * | 1993-09-20 | 1997-05-28 | Jenapharm Gmbh | 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US5391557A (en) * | 1993-10-15 | 1995-02-21 | Eli Lilly And Company | Methods for the treatment of peri-menopausal syndrome |
| ZA959008B (en) * | 1994-10-24 | 1996-09-16 | Schering Ag | Competitive progesterone antagonists for demand-oriented female birth control |
| DE19610635A1 (de) * | 1996-03-11 | 1997-09-18 | Schering Ag | Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie |
| JP2000514785A (ja) * | 1996-06-25 | 2000-11-07 | アクゾ・ノベル・エヌ・ベー | プロゲストゲン―抗プロゲストゲン処方 |
| WO1998005679A2 (en) * | 1996-08-05 | 1998-02-12 | Duke University | Mixed agonists of the progesterone receptor and assays therefor |
| DE19809845A1 (de) * | 1998-03-03 | 1999-09-09 | Jenapharm Gmbh | S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| CZ20012530A3 (cs) * | 1999-01-14 | 2002-02-13 | Bayer Corporation | Substituované 2-aryliminoheterocykly a prostředky s jejich obsahem, k pouľití jako činidla vázajícího receptor progesteronu |
-
2000
- 2000-08-31 PE PE2000000892A patent/PE20010581A1/es not_active Application Discontinuation
- 2000-08-31 EA EA200200285A patent/EA007840B1/ru not_active IP Right Cessation
- 2000-08-31 WO PCT/US2000/023771 patent/WO2001034126A2/en active IP Right Grant
- 2000-08-31 BR BR0013710-3A patent/BR0013710A/pt not_active Application Discontinuation
- 2000-08-31 ES ES00991840T patent/ES2316402T3/es not_active Expired - Lifetime
- 2000-08-31 SI SI200020041A patent/SI20851B/sl not_active IP Right Cessation
- 2000-08-31 RO ROA200200230A patent/RO122180B1/ro unknown
- 2000-08-31 PL PL353931A patent/PL198798B1/pl not_active IP Right Cessation
- 2000-08-31 KR KR1020027002815A patent/KR100729311B1/ko not_active IP Right Cessation
- 2000-08-31 NZ NZ517469A patent/NZ517469A/en unknown
- 2000-08-31 EP EP00991840A patent/EP1605924B1/en not_active Expired - Lifetime
- 2000-08-31 AT AT00991840T patent/ATE413168T1/de not_active IP Right Cessation
- 2000-08-31 SK SK297-2002A patent/SK287121B6/sk not_active IP Right Cessation
- 2000-08-31 UA UA2002032428A patent/UA75339C2/uk unknown
- 2000-08-31 DE DE60040764T patent/DE60040764D1/de not_active Expired - Lifetime
- 2000-08-31 IL IL14841700A patent/IL148417A0/xx unknown
- 2000-08-31 EE EEP200200102A patent/EE200200102A/xx unknown
- 2000-08-31 CO CO00065516A patent/CO5200773A1/es not_active Application Discontinuation
- 2000-08-31 JP JP2001536126A patent/JP2003513908A/ja active Pending
- 2000-08-31 RS YUP-141/02A patent/RS50396B/sr unknown
- 2000-08-31 AR ARP000104537A patent/AR025456A1/es unknown
- 2000-08-31 HU HU0202460A patent/HUP0202460A3/hu unknown
- 2000-08-31 AU AU36332/01A patent/AU781836B2/en not_active Ceased
- 2000-08-31 CZ CZ20020706A patent/CZ301412B6/cs not_active IP Right Cessation
- 2000-08-31 CA CA002383659A patent/CA2383659C/en not_active Expired - Lifetime
- 2000-08-31 CN CN00812257A patent/CN1454088A/zh active Pending
-
2002
- 2002-02-26 BG BG106443A patent/BG65846B1/bg unknown
- 2002-02-26 ZA ZA200201621A patent/ZA200201621B/en unknown
- 2002-02-27 IL IL148417A patent/IL148417A/en not_active IP Right Cessation
- 2002-02-28 MX MXPA02002190A patent/MXPA02002190A/es active IP Right Grant
- 2002-02-28 NO NO20021000A patent/NO20021000L/no not_active Application Discontinuation
- 2002-03-27 LT LT2002037A patent/LT5011B/lt not_active IP Right Cessation
- 2002-03-28 HR HR20020266A patent/HRP20020266A2/hr not_active Application Discontinuation
- 2002-03-28 LV LVP-02-54A patent/LV12942B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK78997A3 (en) | Compounds with progesterone-antagonistic and anti-oestrogen properties intended for combined use in female contraception | |
| AU781835B2 (en) | Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives | |
| CA2383659C (en) | Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) | |
| CA2248841C (en) | Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy | |
| US7629334B1 (en) | Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT) | |
| AU2003206424B2 (en) | Sequential estrogen/progesterone antagonist combination for hormone replacement therapy | |
| ZA200201614B (en) | Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives. | |
| MXPA98007513A (en) | Sequencial combination of estrogen / antagonist of progesterone for therapy of replacement of hormo |